HEALTHCARE PROFESSIONAL RESOURCES
- MetastaticPancreatic CancerCLOSE THE TAB
MPACT Study Videos
Dr. George Kim reviews the MPACT study–the largest multinational Phase III study in metastatic pancreatic cancer (mPC) using ABRAXANE + gemcitabine in the first-line setting.
MPACT Study Design
Dr. Kim presents the study design and results in the MPACT study.MPACT Efficacy
Dr. Kim presents the efficacy results for ABRAXANE in the MPACT study (including OS, ORR, and PFS).MPACT Safety
Dr. Kim presents the safety results for ABRAXANE in the MPACT study.MPACT Dosing
Dr. Kim presents dosing and schedule recommendations for ABRAXANE in the MPACT study.ABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
Knowledge Is Power in Treating mPC
Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring mPC patients receive the most appropriate treatments.
mPC Dosing Card
Dosing Instructions for ABRAXANE mPC indication, including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.
mPC NCCN Flashcard
This useful flashcard summarizes the NCCN Category 1 recommendation for first-line ABRAXANE + gemcitabine for mPC patients with KPS 70-100.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Knowledge Is Power in Treating mPC
Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring mPC patients receive the most appropriate treatments.
mPC Dosing Card
Dosing Instructions for ABRAXANE mPC indication, including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.
mPC NCCN Flashcard
This useful flashcard summarizes the NCCN Category 1 recommendation for first-line ABRAXANE + gemcitabine for mPC patients with KPS 70-100.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
- Metastatic
Breast CancerCLOSE THE TABABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- Advanced Non–SmallCell Lung CancerCLOSE THE TAB
ABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.
- Metastatic Pancreatic CancerCLOSE THE TAB
MPACT Study Videos
Dr. George Kim reviews the MPACT study–the largest multinational Phase III study in metastatic pancreatic cancer (mPC) using ABRAXANE + gemcitabine in the first-line setting.
MPACT Study Design
Dr. Kim presents the study design and results in the MPACT study.MPACT Efficacy
Dr. Kim presents the efficacy results for ABRAXANE in the MPACT study (including OS, ORR, and PFS).MPACT Safety
Dr. Kim presents the safety results for ABRAXANE in the MPACT study.MPACT Dosing
Dr. Kim presents dosing and schedule recommendations for ABRAXANE in the MPACT study.ABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
Knowledge Is Power in Treating mPC
Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring mPC patients receive the most appropriate treatments.
mPC Dosing Card
Dosing Instructions for ABRAXANE mPC indication, including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.
mPC NCCN Flashcard
This useful flashcard summarizes the NCCN Category 1 recommendation for first-line ABRAXANE + gemcitabine for mPC patients with KPS 70-100.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
Knowledge Is Power in Treating mPC
Discover why Philip Agop Philip, MD, professor of oncology and pharmacology at the Karmanos Cancer Center, believes doctors staying up-to-date on the standard of care is essential to ensuring mPC patients receive the most appropriate treatments.
mPC Dosing Card
Dosing Instructions for ABRAXANE mPC indication, including starting dose/schedule and dose modifications for certain treatment-related adverse reactions.
mPC NCCN Flashcard
This useful flashcard summarizes the NCCN Category 1 recommendation for first-line ABRAXANE + gemcitabine for mPC patients with KPS 70-100.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, in combination with gemcitabine.
- Metastatic Breast CancerCLOSE THE TAB
ABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
- Advanced Non–Small Cell Lung CancerCLOSE THE TAB
ABRAXANE Reconstitution Video
This video will guide you through the appropriate process of reconstituting ABRAXANE.
ABRAXANE Full Prescribing Information
Download the Prescribing Information for ABRAXANE.
ABRAXANE is indicated for the first-line treatment of locally advanced or metastatic non–small cell lung cancer, in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.